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Background: Since 2013, several stool banks have been developed following publications reporting on
clinical success of ‘faecal microbiota transplantation’ (FMT) for recurrent Clostridium difficile infections
(CDI). However, protocols for donor screening, faecal suspension preparation, and transfer of the faecal
suspension differ between countries and institutions. Moreover, no European consensus exists regarding
the legislative aspects of the faecal suspension product. Internationally standardized recommendations
about the above mentioned aspects have not yet been established.
Objective: In 2015, the Netherlands Donor Feces Bank (NDFB) was founded with the primary aim of
providing a standardized product for the treatment of patients with recurrent CDI in the Netherlands.
Standard operation procedures for donor recruitment, donor selection, donor screening, and production,
storage, and distribution of frozen faecal suspensions for FMT were formulated.
Results and discussion: Our experience summarized in this review addresses current donor recruitment
and screening, preparation of the faecal suspension, transfer of the faecal microbiota suspension, and the
experiences and follow-up of the patients treated with donor faeces from the NDFB. E.M. Terveer, Clin
Microbiol Infect 2017;23:924
© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Background
Clostridium difficile, recently reclassified as Clostridioides difficile
[1] is capable of inducing diarrhoeal disease (C. difficile infection,
CDI) through production of secreted toxins [2]. After CDI treatment,ted at the European Congress of
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biology and Infectious Diseases. Puthe risk of a recurrence within 8 weeks is 15e25%, which rises to
40e65% in patients with multiple recurrences [2,3]. Recurrences
are associated with clinically severe diarrhoea and persistent
disturbance of the colonic microbiota [4]. Faecal microbiota trans-
plantation (FMT) is therefore a very effective treatment forClinical Microbiology and Infectious Diseases, 9e12 April, 2016 Amsterdam, The
Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
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implementation of FMT in daily clinical practice is hampered by
lack of easily available donor faeces and safety concerns. A
centralized stool bank can overcome these hurdles.
Aim and structure of a non-profit stool bank
The overall and primary aim of a stool bank is to provide on a
(inter)national or regional level, ready to use, high-quality donor
faeces solutions to treat patients with recurrent or refractory CDI.
Second, a central stool bank should enable careful monitoring of
treatment outcome, side effects, and long-term effects of FMT.
Therefore, the stool bank should preferably be facilitated by a well-
equipped biobank to store an aliquot of the donor faeces, and
samples of all delivered faecal suspensions, to guarantee trace-
ability in case of adverse events. A stool bank is ideally entwined
with a clinical microbiological department as the expertise andTable 1
Overview of currently existing donor faeces banks
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a Until 1 April 2017.
b Commercial, social enterprise.equipment to perform both various screening tests, and to process
faecal suspensions is already present. As FMT is not yet an
approved, treatment modality by the European Medicines Agency
(EMA) or US Food and Drug Administration (FDA), commercial stool
banks are not the preferred suppliers. A stool bank working group
should consist of experts in the fields of microbiology, infectious
diseases, gastroenterology, biobanking, and methodology, and if
donor faeces is considered to be a drug, pharmacology. An overview
of the currently existing donor faeces banks is depicted in Table 1.
Similar to the NDFB, most of the donor banks are non-profit and
primarily use FMT for treatment of patients with recurrent CDI.
Legislation of a donor faeces bank
There is still considerable confusion about the regulatory as-
pects of FMT [7e10]. The FDA dictates that adequate informed
consent must be obtained before use of FMT products [11]. In theIndications No. of issued
productsa
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Table 2
Donor screening by laboratory screening of faeces and serum
Laboratory screening serum Laboratory screening faeces
 Hepatitis A (IgM þ IgG)
 Hepatitis B
(HBsAg þ anti-Hbcore)
 Hepatitis C (anti-HCV)
 Hepatitis E (IgM þ IgG)
 HIV (anti-HIV, type 1 and 2)
 Lues; Treponema pallidum (Ig)
 Cytomegalovirus (IgM þ IgG)
 Epstein Barr Virus (IgM þ IgG)
 Strongyloïdes (IgG1/IgG4)a
 Clostridium difficile (PCR)
 Helicobacter pylori (antigen test)
 Bacterial gastroenteritis: (PCR,
followed by culture) Salmonella spp.
Campylobacter spp., Campylobacter
jejuni, C. coli, Shigella spp., Yersinia
enterocolitica and
Y. pseudotuberculosis, Aeromonas spp.,








 Viral pathogens (PCR): Norovirus




 Parasites (PCR): Giardia lamblia,
Entamoeba histolytica,
Cryptosporidium parvum and
C. hominis, Microsporidium spp,
Strongyloïdesa
 Microscopy for ova, cysts, and larvae
[69]: e.g. Blastocystis hominis
Questionnaire: 1 day before donation of faeces
Stool frequency/pattern, general health, use of antibiotics, travel history, sexual
behaviour
When donors pass the questionnaire, faeces is first screened for the presence of
Dientamoeba fragilis and Blastocystis hominis. When negative, other pathogens are
investigated, after which screening of serum is performed.
a If travel history to Middle and South America, Africa, or Asia.
BOX 1
Aim and exclusion criteria of the donor screening by
questionnaire
Aim: Risk assessment of faecal- and/or blood-transmitted
diseases and illnesses associated with a disturbed
microbiota
Exclusion criteria:Age <18 or50, BMI <18.5 or >25 [19,20],
high risk faecal- and or blood-transmittable diseases, recent
antibiotic use (<6 months) [57,58], gastrointestinal com-
plaints (e.g. diarrhoea, obstipation, or irritable bowel-like
symptoms) [59e61], recent travel to endemic areas of
gastrointestinal pathogens, (first-degree relative with) in-
flammatory bowel disease [62], GI malignancy [63], first-
degree relative with a GI malignancy <60 years, substan-
tial comorbidity, various medications, autism [22,64,65],
autoimmune disorders [66], neurological disease [67,68].
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member state is allowed to have its own policy. In The Netherlands,
FMT is currently regarded as an unclassified treatment approach,
which is allowed (if applied safely), for patients with recurrent CDI,
or in the context of an approved investigational study protocol.
Although FMT appears to be a typical transplantation product to
most experts in the field [12], it does not fulfil the criteria for
guidance by the EU tissue and cell transplantation act, because the
cellular component of FMT appears not to be the active substance.
Furthermore, human excretions are excluded by the US act for
tissue and cell transplantations. As a consequence, several Euro-
pean countries considering donor faeces to be a drug (Table 1),
which has major regulatory implications negatively influencing
future availability and pricing of donor stool solutions for FMT.
Application as a drug has the consequence that the proposed drug
would have to be identical in active ingredient, dosage form, route
of administration, quality, and performance characteristics. How-
ever, the complexity of the microbial community in stool and the
variability across stool samples makes it impossible to guarantee
the contents from batch to batch. Furthermore, it would have the
consequence of putting faecal material for use in FMT under the
jurisdiction of hospital pharmacies, requiring storage of the faecal
product in the pharmacy itself. In this regard, common sense and
consultation of the experts in the field may hopefully result in
adjustment of the EU law in concordance with the rapid scientific
developments, enabling future status of donor faeces as a trans-
plantation product.
How to recruit donors?
Historically, FMT donors were conveniently selected among
close relatives and friends of patients with the underlying idea that
they would have at least a partially shared microbiome, increasing
the chances of success [13], and limiting the risk of pathogen
transmission [13,14]. However, later evidence showed that FMT
with donor faeces from unrelated donors was as effective [5,15].
This finding provided an opportunity for a better standardized,
safer, faster, and cheaper method of donor selection, screening, and
faecal suspension preparation.
The NDFB acquired many potentially interested donors after
announcing the opening of the first Dutch stool bank via local and
national media (e.g. paper, national news). One of several options
for recruitment of faeces donors is from established blood donors,
as this has the advantage of previously screened, healthy, and
motivated volunteers. An important difference in donor recruit-
ment in The Netherlands and most other European countries
(except Germany) compared with the USA is that it is prohibited to
offer a paid reimbursement for blood (or stool) donations. This
prohibition is in line with the blood donating advice of the World
Health Organization, which states that the safest blood donors are
voluntary, non-remunerated donors [16]. As it is important to limit
the time between defecation and delivery of the faeces, to preserve
as many anaerobes as possible, donors should be recruited in the
near proximity of stool banks, such as non-healthcare workers of
the hospital and personnel of companies in the neighbourhood.
Donor screening by questionnaire and interview
All potential donors are extensively screened by a questionnaire
and a personal interview concerning risk factors for transmissible
diseases and factors influencing the intestinal microbiota (Table 2).
The NDFB has applied an arbitrary age limit of 18 to 50 years,
assuming that above the age of 50 years a significant increase of
comorbidities with a less stable microbiota can be present [17]. A
body mass index (BMI) > 25 kg/m2 is also an exclusion criterion, asobesity may also be associated with a specific microbiota compo-
sition [18]. Moreover, one case-report, and an experimental animal
study suggesting new-onset obesity after infusion of donor faeces
of an overweight donor have been reported [19,20]. Any other
gastrointestinal disorder (e.g. irritable bowel syndrome (IBS),
Crohn's disease, or ulcerative colitis) also qualifies as an exclusion
criterion of donation [21]. Other exclusion criteria that have been
shown to be related to aberrant microbiota composition are
depicted in Box 1 [22]. The list of exclusion criteria is likely to
expand in the future when other conditions are found to be asso-
ciated with an altered microbiota composition.
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Extensive laboratory analysis should be performed to identify
potential pathogens transmissible by faecal transfusion. An over-
view of all tests performed by the NDFB is shown in Table 2. The
pathogens included in the blood-screening programme correspond
with the screening protocols for blood donors and are generally
agreed among the different stool banks [14,15,23e27]. However,
screening protocols for detection of specific microorganisms in the
intestinal tract differ between stool banks, and evolve with time
and new insights, as there is no consensus guideline. This applies,
for example, to screening for the presence of multi-drug-resistant
(MDR) organisms, including ESBL- and carbapenemase-producing
bacteria, vancomycin-resistant enterococci, and methicillin-
resistant Staphylococcus aureus. Screening for the (asymptomatic)
presence of rotavirus is not routinely performed by stool banks, but
as rotavirus is often found in asymptomatic donors, especially in
winter, we included this in our protocol [26,28]. Adenovirus type
40/41, Sapovirus and Astrovirus are associated with mild gastro-
intestinal diarrhoea and are therefore also screened [29]. Entero-
virus and Parechovirus are usually asymptomatic but can cause skin
disease (and foot-and-mouth disease), pleurodynia, myocarditis,
and meningitis [30,31]. Adenovirus non-40/41 can cause myocar-
ditis [32]. In addition, faeces is screened for hepatitis E, which is
often found in asymptomatic (blood) donors [33]. To prevent
transmission and development of systemic infections, potential
donors are screened with PCR for all the above-mentioned viruses
(see also Table 2 for the total list of pathogens).
The significance of Dientamoeba fragilis and Blastocystis hominis
as enteropathogens is less clear [34e37]. D. fragilis and B. hominis
are commonly found in faecal samples of both symptomatic and
asymptomatic individuals [37,38]. Prevalence varies considerably
depending on geographic location, the group studied, and diag-
nostic methods used [34]. The cell wall of B. hominis is fragile and
disrupts easily; storage of microscopically positive stool samples in
10% glycerol at 80C results in complete lysis and negative mi-
croscopy after the samples are thawed and reinvestigated (un-
published observation). Despite the uncertainty of B. hominis and
D. fragilis pathogenicity, colonization may be considered an indi-
cator of a suboptimal microbiota composition [39]. Therefore,
positive individuals are excluded from donorship for NDFB.
The serostatus of the donor is determined for Epstein-Barr virus
(EBV) and cytomegalovirus (CMV). Immunocompromised patients
will be matched accordingly for safety reasons. However, the risk of
transmission is not established and we await the results of ongoing
study regarding the risk of CMV transmission resulting from FMT
(TRANSDECMV Clin Trial Gov: NCT02694484).
Approximately 2 months after the initial screening, a new donor
sample of faeces and blood are screened again, using similar tests as
applied at entry of the programme (see Table 2), except for CMV
and EBV which are repeated once a year (in case of a negative
serostatus. After a successful second screening, the donor faecal
suspensions collected until 2 weeks prior to the second screening
are released for patient treatment. This quarantine period mini-
mizes the risk for transmissible diseases.
Collection, preparation, and storage of donor faeces
suspensions
It is generally believed that a high viability of bacteria in stools
increases the chance of successful FMT. As the majority of faecal
bacteria are anaerobic, faeces must be processed within 6 hours of
defecation [5,6]. To prevent environmental contamination, faeces is
collected by the donor in a faecal container (e.g. Fecotainer). For
suspension, approximately 60 g of donor faeces is used based onthe data of a systematic review suggesting a decreased cure rate
with <50 g [40]. The faeces is homogenized with saline using a
mortar and pestle, whereas some laboratories use a commercial
blender [15,25]. Disadvantages of blenders are difficulties with
appropriate sterilization and aerosolization of the faeces. A metal
sieve (mesh 300 mm) is used to remove undigested food fragments.
The faecal suspension is then concentrated by centrifugation
(15 min, 6000 g) [25] and glycerol is added as cryoprotectant to a
final concentration of 10% in a total end volume of 200 mL. A recent
study showed that frozen faecal suspension is equally effective as a
fresh faecal suspension for the treatment of CDI [41]. This allows
stool samples to be stored at80C for a longer period of time until
the donor has been retested prior to actual use of the donor faeces.
Clinical success of frozen suspensions is reported until 5 to
6 months of storage at 80C, but could be much longer, in theory.
Like OpenBiome, the NDFB uses a storing period of 2 years.
How to apply safety measures and include quality controls
At the Leiden University Medical Center (LUMC), storage of the
FMT suspensions is accommodated by the certified centralized
biobanking facility in a specific 80C freezer with connected
alarm notification to guarantee continuous registration of the
storage. In addition, the biobanking facility uses a dedicated bio-
banking information and management system (BIMS SampleNa-
vigator) for coding, registration, tracking, and tracing of the
biosamples. FMT suspensions, in combination with a small portion
of the original faeces and a 2 cc portion of the FMT suspension, are
stored under a unique donor code with a successive suffix number
for donation time and date for retrospective quality assessment.
Information on the FMT suspension labels includes donor code,
suspension number, production and expiration date, volume, and
storage temperature instruction. Distribution of the FMT upon
granted request by the NDFB is provided by dry-ice shipment
through a certified Biologistic Courier service. Registration in a
BIMS-related database for the shipped FMT suspensions, including
recipient institution and requestor information, is provided so that
biovigilance tracing can be performed in cases of adverse events.
An important aim of the NDFB is to recognize complications of
FMT. Therefore, systematic follow-up of both patients and donors is
performed with signed informed consents. The NDFB collects re-
cipients' faeces and clinical data on the day of FMT and approxi-
mately 3 weeks after the procedure. Furthermore, clinical
information including abdominal complaints, development of
diarrhoea, and adverse events (e.g. nausea, bloating, abdominal
pain, belching, vomiting) is collected. No systematic long-term
follow-up has been scheduled yet to register development of
autoimmune diseases, malignancies, and other potentially
microbiome-associated syndromes both in donors and patients.
However, all faeces and serum samples have been stored in the
biobank and remain available for analysis.
How to determine eligibility of patients with recurrent
Clostridium difficile infection for FMT
As the effectiveness of FMT has only been recognized by the
authorities for recurrent CDI, it is extremely important to diagnose
recurrent CDI both with the presence of clinical symptoms and
positive microbiological tests. Therefore, written requests for FMT
treatment with a standardized form are evaluated by at least two
clinical members of the NDFB board to determine eligibility of the
patient. It is required that patients have a laboratory-documented
episode of recurrent CDI following at least one course of adequate
CDI antibiotic therapy (10 days 125mg vancomycin QID;10 days
metronidazole 500 mg TID; 10 days 200 mg fidaxomicin BID).
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three unformed stools per 24 hours for 2 consecutive days; or at
least eight unformed stools per 48 hours) within 8 weeks of
cessation of antibiotic therapy in combination with a positive
diagnostic test for C. difficile. We strongly recommend a two-stage
testing algorithm, as recently advised by the C. difficile ESCMID
diagnostic guideline [42]. In particular, a positive test for the
presence of free toxins in faeces samples (e.g. by EIA) is a prereq-
uisite, especially for patients with comorbidity of the intestinal
tract, such as inflammatory bowel disease (IBD). If laboratories only
use PCR to detect toxin genes of C. difficile, we advise to sending a
fresh faeces sample to a reference laboratory for toxin detection, as
C. difficile (spores) can persist after successful treatment and may
reflect colonization.
For a first recurrence of CDI, it is advised to first treat the patient
with another course of antibiotics. Fidaxomicin could be considered
because of its potentially relapse-reducing effect resulting from its
narrow antibiotic spectrum [43]. In general, FMT is advised in pa-
tients with multiple recurrences. However, in some cases of severe,
therapy refractory CDI, FMT could be considered for a first recur-
rence [27,44]. A recently completed study suggests that intrave-
nously administered humanized monoclonal antibodies against
C. difficile toxin B (bezlotoxumab) protect against (multiple)
recurrent CDI. However, it is yet unclear which patients really
benefit from this very expensive treatment strategy [45].
Pregnancy, severe food allergy, and antibiotic usage other than
for C. difficile on the day of expected infusion are exclusion criteria
for FMT treatment. Although, recently, the first case report of suc-
cessful and safe FMT in a pregnant patient was published [46]. All
potential risks, benefits, logistics, and procedural details are dis-
cussed with the patient by the treating physician.Table 3
Experiences of the NDFB with donor screening
Potential donors Action Exclusion reasonsa
165 Request of information by email 62% age >50 years, 26
faeces <2 hour after d
6% BMI >25, 6% other
71 Extended questionnaire 17.2% age >50 years, 2
(history of) depression
7.1% profession of hea
to deliver faeces <2 ho
IBD, 4.3% anorexia, 2.9
2.9% autism, 2.9% (risk
2.9% profession with f
abundant flatulence
21 First faeces screening 42.9% D. fragilis, 4.8% D
4.8% D. fragilis and C. j
10 Serum screening None
10 Repeated faeces screening 20% B. hominis, 10% ES
(after 0, 2, and 6 mon
Temporarily excluded
rotavirus carriership (
a Some volunteers have multiple exclusion criteria.
b 1 minus cumulative proportion of excluded donors.
c Higher risk of temporary carriership of pathogens.
d Antibiotic use in the previous 6 months.
e Close relative with colon carcinoma, onset below age of 60.
f Treated, included as donor 6 months later.What is the procedure of FMT?
If the patient is eligible for treatment with FMT, donor faeces
suspension is transported to the referring hospital on dry ice. Prior
to transplantation, the faeces suspension is thawed (overnight in a
4C refrigerator or during 5 hours at room temperature), based on
literature and our expert opinion [15,41,47]. The donor faeces sus-
pension may be kept at room temperature for up to 3 hours or
refrigerated at 4C for up to 6 hours. Samples should never be re-
frozen, because freeze-thaw cycles may compromise stability and
efficacy of the sample, possibly because of loss of viability. To
eradicate vegetative cells of C. difficile, prior to FMT (until 1 day
before the procedure), patients receive vancomycin (125e250 mg
QID) for a minimum of 4 days, followed by 2 L of bowel lavage 1 day
prior to FMT [5]. Whether bowel lavage can be excluded from the
protocol is currently a matter of discussion, as recent reports have
shown similar efficacy for FMT without bowel lavage [48e50]. The
treating physician is advised to avoid antibiotics in FMT patients
during the first month after FMT unless strictly necessary, and
preferably keep doses as small as possible. FMT is generally per-
formed by infusion of a donor faeces solution through a gastric or
duodenal tube [5], colonoscope [6], or enema [40]. All infusion
routes have advantages and disadvantages, and the ideal method
should be evaluated for each individual. The FMT procedure can be
performed by the treating physician and does not justify standard
referral to a specialized centre. Physicians are instructed how to
perform FMT, and if necessary, FMT training sessions are offered. In
The Netherlands, FMT via duodenal tube is preferred because it is
generally well tolerated by patients, and is less invasive compared
with colonoscopy, especially in an inflamed bowel as with severe
CDI [5,51,52]. On the day of FMT treatment, a duodenal tube isExcluded (n) Suitable donorsb (n)
% unable to deliver
efecation,
94 (57%) 71 (43%)
7.1% BMI >25, 14.3%
, 8.5% comorbidity/medicine use,
lthcare workerc, 7.1% inability
ur, 7.1% (close relative with)
% recent use of antibioticsd,
factors for) colon carcinomae,
requent travelling, 2.9%
50 (70.4%) 21 (12.7%)
. fragilis and B. hominis,
ejuni, 4.8% E. histolyticaf
11 (52.3%) 10 (6.1%)
0 (0%) 10 (6.1%)
BL E. coli, 30% donor withdrawal
ths)
: acute diarrhoea (for 3 months),
for 2 weeks)
6 (60%) 4 (2.4%)
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use of an electromagnetic imaging system (e.g. Cortrak TM). The
thawed faeces solution of approximately 200 mL is slowly infused
through the duodenal tube with a 50 cc syringe, at a rate of 10 cc/
min, after which the tube is flushed with 50 mL tap water. Thirty
minutes after FMT, the duodenal tube is removed and patients are
monitored for 2 hours. If FMT through a duodenal tube is contra-
indicated (i.e. because of hampered bowel passage or higher risk
of aspiration), FMT is performed via colonoscopy. We generally do
not recommend enemas, because of the need for repeated FMTs to
achieve a high cure rate with enemas [53].
NDFB experience during May-January 2017
In March 2016, the opening of NDFB was reported in various
local and national newspapers and broadcast on radio and televi-
sion programmes, accompanied by an invitation for volunteers to
register as donors. Subsequently, 165 volunteers registered and
were informed by email about the procedure and asked to complete
an online questionnaire. After this evaluation only 21 potential
donors (12.7%) were screened for the presence of transmissible
diseases (Table 3). Nine (5.5% of initial responders) volunteers
passed the screening and were invited to donate. This percentage is
low, although in line with earlier reports on donor screening
[29,54e56]. The faecal suspensions were quarantined for 2 months,
after which the donors were re-screened. Two volunteers had to
temporarily stop donating for 3 months because of an episode of
acute diarrhoea. Four donors did not pass a re-screening: two
carried B. hominis, one an ESBL-positive E. coli (exclusion for at least
6 months), and one donor a rotavirus (indication for re-screening of
the previous donated samples and exclusion for 2 weeks); this
underlines the importance of a quarantine period. As a substantial
portion of donors only donate temporarily, donor recruitment is a
continuous process.
In May 2016, the first FMT with a donor faeces suspension of the
NDFB was performed. In the first 9 months after its opening, 31
faeces suspensions to 18 different hospitals throughout The
Netherlands have been distributed for treatment with FMT. We
noted a cure rate of 84%, which is in line with the earlier reported
randomized controlled trials [5,6].
Business plan
In The Netherlands, disease entities are reimbursed regardless of
the given treatment (e.g. for recurrent CDI; vancomycin or fidax-
omicin or FMT) when the patient is treated in daycare. A business
case to calculate the break-even point of producing safe faeces
samples for FMT was determined for the NDFB. We considered (i)
recruitment, screening, and selecting of suitable donors, (ii) dona-
tion of faeces by donors and periodic rescreening, (iii) assessment
of eligibility of patients' demand for FMT, (iv) supply of a safe faecal
suspension, and (v) post-treatment monitoring. Costs covering
hospital staff involved (medical, technical, administrative, advi-
sory), laboratory tests, storage, and biobanking amount to a unit
cost per patient to be treated (including 10% re-treatment in case of
initial non-response) of V899 in case of 100 patients yearly, drop-
ping to V785 in case of 400 patients yearly to account for econo-
mies of scale.
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